Researchers ID genetic marker for sporadic breast cancer

May 28, 2013

Medical researchers at the University of Alberta have pinpointed a genetic marker for sporadic breast cancer – one of a handful identified to date in Caucasians.

Researchers have identified many for familial breast cancers, but not for sporadic breast cancer which accounts for 80 per cent of all cases. Sambasivarao Damaraju, a professor with the Faculty of Medicine & Dentistry and a researcher at the Cross Cancer Institute, worked with his team to scan the DNA of about 7,200 Alberta women, including those who have had sporadic breast cancer and those who have not had cancer. Their genomes were scanned from DNA isolated from blood.

The results? Women who had sporadic breast cancer frequently had a genetic marker on chromosome 4 – a marker that has never been associated with familial breast cancer cases.

"The frequency of this marker occurring was statistically significant," says Damaraju, who works in the Department of Laboratory Medicine & Pathology. "Genetic factors that predispose women to breast cancer is a subject of intense investigation in the research world. While 60 to 70 genetic risk factors have been identified for familial breast cancer, we don't know much about the genetic risk factors for sporadic breast cancer. So this finding is exciting, and shows us more research is needed in this area."

The team's findings were recently published in the peer-reviewed journal, PLoS One. Damaraju noted the team, which included co-author John Mackey and PhD student Yadav Sapkota, was multi-disciplinary, including basic scientists, medical oncologists, biostatisticians and epidemiologists. He also acknowledged the initial contributions to this work from previous trainees, Malinee Sridharan and Badan S. Sehrawat. Overall, he collaborated with colleagues from the U of A's School of Public Health, the Department of Oncology, and the Department of Agricultural, Food and Nutritional Sciences, as well as colleagues from the Cross Cancer Institute and Alberta Health Services.

Damaraju and his team are continuing their work in this very young field (the first genetic marker for breast cancer predisposition was reported in 2007). He says more research is needed to identify genetic markers for sporadic breast cancer, but that large scale screening to identify those at risk is still years away.

Lifestyle factors account for two-thirds of the risk associated with breast cancer, while the remaining one-third of the risk is attributed to genetics, Damaraju noted.

The research was funded by the Alberta Cancer Foundation and the Canadian Breast Cancer Foundation – Prairies/NWT region.

"We are pleased to see donor dollars having a direct impact on outcomes that are important to Albertans – in this case identifying a genetic marker of a specific breast cancer may lead to earlier detection and improved treatment options," says Myka Osinchuk, CEO of the Alberta Cancer Foundation. "For years, the Alberta Cancer Foundation has invested in the 'biobank' that has given this research team access to the blood and tissue samples used in this study, and we recently confirmed our support with more funding. It is exciting to see how this comprehensive collection of tumour and tissue samples is starting to provide answers to key clinical questions."

Tracy Sopkow, VP, Cause Related Programs with the Canadian Breast Cancer Foundation – Prairies/NWT Region, added: "Our organization believes in supporting innovative research that has the potential to make a real, tangible difference. We're proud to support Dr. Damaraju and his team in their quest to identify genetic markers for sporadic because the knowledge gained has the potential to change the future for thousands of women."

Explore further: Researchers find DNA marker that predicts breast cancer recurrence

Related Stories

Researchers find DNA marker that predicts breast cancer recurrence

January 16, 2013
Medical researchers at the University of Alberta tested the DNA of more than 300 women in Alberta and discovered a 'genetic marker' method to help accurately profile which women were more apt to have their breast cancer return ...

Polygenic risk score helpful for women with familial breast CA

December 18, 2012
(HealthDay)—For women affected by familial breast cancer, a polygenic risk score based on 22 genomic variants can identify women at high-risk of breast cancer, according to a study published in the Dec. 10 issue of the ...

Cosmetic breast implants may adversely affect survival in women who develop breast cancer

April 30, 2013
Cosmetic breast implants seem to adversely affect the survival of women who are subsequently diagnosed with breast cancer, finds a small study published on BMJ website today.

Massive study closes in on cancers risk markers

May 15, 2013
Cancer research has taken a huge leap forward with scientists now able to identify more than 80 genetic markers found to increase the risk of breast, ovarian and prostate cancer. The COGS international research initiative ...

Nearly half of breast cancer patients at risk of having BRCA mutations not sent for genetic testing

April 8, 2013
Only 53 percent of newly diagnosed breast cancer patients who were at high risk of carrying a BRCA 1 or BRCA 2 mutation – based on age, diagnosis, and family history of breast or ovarian cancer – reported that their doctors ...

Breast cancer type linked to paternal cancer

November 28, 2011
The risk of breast cancer is increased by genetic and lifestyle factors such as the inherited BRCA2 gene, age of having first child, or use of hormone replacement therapy (HRT). New research published in BioMed Central's ...

Recommended for you

Study may explain failure of retinoic acid trials against breast cancer

July 25, 2017
Estrogen-positive breast cancers are often treated with anti-estrogen therapies. But about half of these cancers contain a subpopulation of cells marked by the protein cytokeratin 5 (CK5), which resists treatment—and breast ...

Physical activity could combat fatigue, cognitive decline in cancer survivors

July 25, 2017
A new study indicates that cancer patients and survivors have a ready weapon against fatigue and "chemo brain": a brisk walk.

Breaking the genetic resistance of lung cancer and melanoma

July 25, 2017
Researchers from Monash University and the Memorial Sloan Kettering Cancer Center (MSKCC, New York) have discovered why some cancers – particularly lung cancer and melanoma – are able to quickly develop deadly resistance ...

New therapeutic approach for difficult-to-treat subtype of ovarian cancer identified

July 24, 2017
A potential new therapeutic strategy for a difficult-to-treat form of ovarian cancer has been discovered by Wistar scientists. The findings were published online in Nature Cell Biology.

Immune cells the missing ingredient in new bladder cancer treatment

July 24, 2017
New research offers a possible explanation for why a new type of cancer treatment hasn't been working as expected against bladder cancer.

Anti-cancer chemotherapeutic agent inhibits glioblastoma growth and radiation resistance

July 24, 2017
Glioblastoma is a primary brain tumor with dismal survival rates, even after treatment with surgery, chemotherapy and radiation. A small subpopulation of tumor cells—glioma stem cells—is responsible for glioblastoma's ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.